Full Text View
Tabular View
No Study Results Posted
Related Studies
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This study has been completed.
Study NCT00786422   Information provided by Bayer

First Received on November 5, 2008.   Last Updated on August 9, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Venous Thrombosis
Deep Vein Thrombosis
Additional conditions recognized in this trial
Pulmonary Embolism
Thrombosis
Venous Thromboembolism
More general conditions related to this trial
Cardiovascular Diseases
Embolism
Embolism and Thrombosis
Lung Diseases
Respiratory Tract Diseases
Thromboembolism
Vascular Diseases
Interventions listed in this trial
Rivaroxaban (Xarelto,BAY59-7939)
Additional drug interventions recognized in this trial
Cardiovascular Agents
Fibrin Modulating Agents
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services